Search Results - "Perja, M."

Ultrasonography of haemophilic arthropathy by MUÇA-PERJA, M., RIVA, S., GROCHOWSKA, B., MANGIAFICO, L., MAGO, D., GRINGERI, A.

“…Imaging is an essential tool for evaluation and monitoring of haemophilic arthropathy. Ultrasonography is increasingly used for joint assessment, due to its…”
Get full text

Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance by MANGIAFICO, L., PERJA, M., FUSCO, F., RIVA, S., MAGO, D., GRINGERI, A.

“…Highly active antiretroviral therapy (HAART) of HIV+ patients with haemophilia poses specific questions on safety and effectiveness because of long‐lasting HIV…”
Get full text

A prospective clinical trial of implantable central venous access in children with haemophilia by Santagostino, E, Gringeri, A, Muca-Perja, M, Mannucci, P M

“…To assess the risks associated with the use of central venous ports in children with haemophilia, 15 HIV‐negative patients were prospectively evaluated. Port…”
Get full text

High Prevalence of Serum Cryoglobulins in Multitransfused Hemophilic Patients With Chronic Hepatitis C by Santagostino, E., Colombo, M., Cultraro, D., Muça-Perja, M., Gringeri, A., Mannucci, P.M.

“…The prevalence, clinical relevance, and risk factors of serum cryoglobulins in hemophilic patients with chronic hepatitis C virus (HCV) infection are unknown…”
Get full text

A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) by GRINGERI, A., LUNDIN, B., VON MACKENSEN, S., MANTOVANI, L., MANNUCCI, P. M.

“…Background: Prevention of arthropathy is a major goal of hemophilia treatment. While studies in adults have demonstrated an impact of prophylaxis on the…”
Get full text

Tat toxoid as a component of a preventive vaccine in seronegative subjects by GRINGERI, A, SANTAGOSTINO, E, ZAGURY, D, MUCA-PERJA, M, LE BUANEC, H, BIZZINI, B, LACHGAR, A, ZAGURY, J.-F, RAPPAPORT, J, BURNY, A, GALLO, R. C

“…Because administration of Tat protein, the HIV-1 toxin that induces immunosuppression and apoptosis, may be deleterious to the host immune system, a chemically…”
Get full text

High Prevalence of Serum Cryoglobulins in Multitransfused Hemophilic Patients With Chronic Hepatitis C by Santagostino, E., Colombo, M., Cultraro, D., Muça-Perja, M., Gringeri, A., Mannucci, P.M.

“…The prevalence, clinical relevance, and risk factors of serum cryoglobulins in hemophilic patients with chronic hepatitis C virus (HCV) infection are unknown…”
Get full text

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat Toxoid by Le Buanec, H, Lachgar, A, Bizzini, B, Zagury, JF, Rappaport, J, Santagostino, E, Muça-Perja, M, Gringeri, A

“…Extracellular Tat can act as a viral toxin on uninfected cells of different tissues, including the CNS and the immune system, thus in order to immunize humans…”
Get full text

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients by Gringeri, A, Santagostino, E, Muça-Perja, M, Mannucci, P M, Zagury, J F, Bizzini, B, Lachgar, A, Carcagno, M, Rappaport, J, Criscuolo, M, Blattner, W, Burny, A, Gallo, R C, Zagury, D

“…To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HIV-1 vaccine using…”
Get more information

Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum — an adjuvant to antiretroviral tritherapy by Zagury, D., Lecoq, H., Gervi, I., Le Buanec, H., Zagury, J.F., Bizzini, B., Burny, A., Hermans, P., Perja, M., Santagostino, E., Gringeri, A.

“…HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However, since the antiretroviral agents used in HAART may also…”
Get full text

Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response by GRINGERI, A., MUSSO, R., MAZZUCCONI, M. G., PISEDDU, G., SCHIAVONI, M., PIGNOLONI, P., MANNUCCI, P. M.

“…Immune tolerance induction (ITI) is effective in approximately 70% of haemophilia patients with inhibitors. Poor prognostic factors are age >6 years, ITI…”
Get full text

Long‐term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study by Santagostino, Elena, Gringeri, Alessandro, Berardinelli, Luisa, Beretta, Claudio, Muça‐Perja, Myrvet, Mannucci, Pier Mannuccio

“…Infectious and thrombotic complications limit the long‐term use of subcutaneous ports as venous accesses for children with haemophilia. This study has…”
Get full text

Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate by GRINGERI, A., MONZINI, M., TAGARIELLO, G., SCARAGGI, F. A., MANNUCCI, P. M.

“…A solvent‐detergent virus‐inactivated plasma‐derived FVIII concentrate (SD‐pdFVIII) has been employed for treatment of Italian patients with haemophilia A for…”
Get full text

Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-α immunization : A 30-month follow-up report by GRINGERI, A, SANTAGOSTINO, E, PBIKA, J. P, LACHGAR, A, FALL, L.-S, CHAMS, V, FELDMAN, M, HERMANS, P, ZAGURY, J. F, BIZZINI, B, MUSICCO, M, ZAGURY, D, CUSINI, M, MUCA-PERJA, M, MARINONI, A, MANNUCCI, P. M, BURNY, A, CRISCUOLO, M, LU, W, ANDRIERU, J. M

“…Twenty-seven HIV-1-infected patients, 16 at early stage of disease and without concomitant antiretroviral therapy and 11 at more advanced stage of disease…”
Get full text

Arterio-venous fistula as permanent access for home treatment in children with hemophilia: long-term safety and feasibility by Santagostino, E., Gringeri, A., Muca-Perja, M., Berardinelli, L., Mannucci, P. M.

Get full text

Identification of Immunodominant Epitopes in Inactivated Tat-Vaccinated Healthy and HIV-1-Infected Volunteers by Noonan, Douglas M, Gringeri, Alessandro, Meazza, Raffaella, Rosso, Ombretta, Mazza, Stefania, Muça-Perja, Myrvet, Le Buanec, Hélène, Accolla, Roberto S, Albini, Adriana, Ferrini, Silvano

“…We analyzed the epitopes and the molecular forms of Tat recognized by the antibodies raised by Tat-toxoid vaccination in both healthy and HIV-infected…”
Get full text

Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum : an adjuvant to antiretroviral tritherapy : AIDS intensive virostatic therapy by ZAGURY, D, LECOQ, H, GRINGERI, A, GERVI, I, LE BUANEC, H, ZAGURY, J. F, BIZZINI, B, BURNY, A, HERMANS, P, PERJA, M, SANTAGOSTINO, E

Get full text

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat Toxoid : AIDS sciences by LE BUANEC, H, LACHGAR, A, BIZZINI, B, ZAGURY, J. F, RAPPAPORT, J, SANTAGOSTINO, E, MUCA-PERJA, M, GRINGERI, A

Get full text